Status:
UNKNOWN
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Guangzhou First People's Hospital
Zhujiang Hospital
Conditions:
Autologous Hematopoietic Stem Cell Transplantation
Conditioning
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell trans...
Eligibility Criteria
Inclusion
- Multiple Myeloma patients
- Achieving at least VGPR after chemotherapy, then mobilizing and collecting of peripheral blood stem cells
Exclusion
- Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- Patients with any conditions not suitable for the trial (investigators' decision
Key Trial Info
Start Date :
January 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT03385096
Start Date
January 2 2018
End Date
December 1 2021
Last Update
February 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515